← Leaderboards
Mark A Feitelson
Thomas Jefferson University
$9,601,309
Attributed
$9,601,309
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$9,601,309 · 7
By mechanism
R01$9,601,309 · 7
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineBaseLiver DiseasesPrimary Carcinoma Of The Liver CellsHepatitis B VirusChronicHepatitis B Virus GroupHepatocellular CarcinomaTumorIn VivoHepatitis BCirrhosisHepatocyteCellsHepatitisAppearancePathogenesisResponseHepatitis B X-ProteinLiverAntigensSerumHepatitis B AntigensMutant
Grant awards (33)
Combination therapies for chronic HBV, liver disease and cancer$347,054
R01 · FY2012 · AI · contact PI
Combination therapies for chronic HBV, liver disease and cancer$347,054
R01 · FY2011 · AI · contact PI
Combination therapies for chronic HBV, liver disease and cancer$350,559
R01 · FY2010 · AI · contact PI
Beta-Catenin Signaling in HBxAg Mediated HCC.$258,530
R01 · FY2010 · CA · contact PI
Combination therapies for chronic HBV, liver disease and cancer$354,100
R01 · FY2009 · AI · contact PI
Early antibody markers of HCC$280,899
R01 · FY2009 · CA · contact PI
Beta-Catenin Signaling in HBxAg Mediated HCC.$256,657
R01 · FY2009 · CA · contact PI
Combination therapies for chronic HBV, liver disease and cancer$366,600
R01 · FY2008 · AI · contact PI
Early antibody markers of HCC$276,457
R01 · FY2008 · CA · contact PI
Beta-Catenin Signaling in HBxAg Mediated HCC.$267,147
R01 · FY2007 · CA · contact PI
Beta-Catenin Signaling in HBxAg Mediated HCC.$258,530
R01 · FY2007 · CA · contact PI
HBV-Ethanol Interactions in Liver Disease$212,586
R01 · FY2007 · AA · contact PI
Early antibody markers of HCC$139,272
R01 · FY2007 · CA · contact PI
Early antibody markers of HCC$129,662
R01 · FY2007 · CA · contact PI
HBV-Ethanol Interactions in Liver Disease$122,358
R01 · FY2007 · AA · contact PI
HBV-Ethanol Interactions in Liver Disease$344,948
R01 · FY2006 · AA · contact PI
Early antibody markers of HCC$277,094
R01 · FY2006 · CA · contact PI
Beta-Catenin Signaling in HBxAg Mediated HCC.$275,864
R01 · FY2006 · CA · contact PI
HBV-Ethanol Interactions in Liver Disease$353,250
R01 · FY2005 · AA
Early antibody markers of HCC$296,543
R01 · FY2005 · CA
HBV-Ethanol Interactions in Liver Disease$353,250
R01 · FY2004 · AA
MECHANISMS OF HBV X MEDIATED HCC$318,000
R01 · FY2004 · CA
HBV-Ethanol Interactions in Liver Disease$378,250
R01 · FY2003 · AA
MECHANISMS OF HBV X MEDIATED HCC$318,000
R01 · FY2003 · CA
TRANSGENIC MOUSE FOR HBV ASSOCIATED HCC RISK FACTORS$350,322
R01 · FY2002 · CA
MECHANISMS OF HBV X MEDIATED HCC$318,000
R01 · FY2002 · CA
SENESCENCE AND APOPTOSIS IN HBV ASSOCIATED HCC$249,614
R01 · FY2002 · CA
TRANSGENIC MOUSE FOR HBV ASSOCIATED HCC RISK FACTORS$340,197
R01 · FY2001 · CA
MECHANISMS OF HBV X MEDIATED HCC$318,000
R01 · FY2001 · CA
SENESCENCE AND APOPTOSIS IN HBV ASSOCIATED HCC$242,344
R01 · FY2001 · CA
TRANSGENIC MOUSE FOR HBV ASSOCIATED HCC RISK FACTORS$351,604
R01 · FY2000 · CA
MECHANISMS OF HBV X MEDIATED HCC$313,280
R01 · FY2000 · CA
SENESCENCE AND APOPTOSIS IN HBV ASSOCIATED HCC$235,284
R01 · FY2000 · CA